Prevalence and significance of asymmetric septal hypertrophy in hypertension: an echocardiographic and clinical study

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Hypertension (n=613). Intervention: Asymmetric septal hypertrophy vs. Symmetrical left ventricular hypertrophy or no left ventricular hypertrophy. Primary outcome: Prevalence of asymmetric septal hypertrophy.

Key Result

Asymmetric septal hypertrophy was present in 5% of hypertensive patients, and its development was not primarily determined by hypertension severity, renin-angiotensin system, or sympathetic activity.

Study Design

Type

Observational (n=613)

Structured PICO

What is the prevalence and what are the clinical determinants of asymmetric septal hypertrophy in hypertensive patients?

Population

613 hypertensive patients who underwent echocardiographic examinations over a one-year period, with a subset of 101 undergoing complete clinical evaluation.

Comparator

Patients with symmetrical left ventricular hypertrophy (n=38) and without left ventricular hypertrophy (n=54)

Outcome

Prevalence of asymmetric septal hypertrophy (ASH) and its clinical determinants (hypertension severity, renin-angiotensin system, sympathetic nerve activity)surrogate

Asymmetric septal hypertrophy occurs in about 5% of hypertensive patients, but its presence is not directly linked to the severity of hypertension or neurohormonal activation.

Abstract

To assess the prevalence of asymmetric septal hypertrophy (ASH) in hypertensive patients, 613 echocardiographic examinations performed over a period of one year were reviewed. Asymmetric septal hypertrophy (defined by an echocardiographic interventricular septum to left ventricular free wall thickness ratio of greater than or equal to 1.3 and by the presence of suggestive two-dimensional echocardiographic abnormalities) was found in 28 patients (5%). Clinical characteristics of asymmetric septal hypertrophy were assessed in 101 patients who underwent a complete evaluation. Patients with asymmetric septal hypertrophy (n = 9) were compared with patients with echocardiographic symmetrical left ventricle hypertrophy (n = 38) and without left ventricular hypertrophy (n = 54). Our results indicate that neither the severity of hypertension, nor the renin-angiotensin system nor sympathetic nerve activity appear to be the primary determinants in the development of asymmetric septal hypertrophy.

Demander à l'IA

Bookmark

Demander à l'IA

Bookmark

Cite This Study

Wicker et al. (Wed,) conducted a observational in Hypertension (n=613). Asymmetric septal hypertrophy vs. Symmetrical left ventricular hypertrophy or no left ventricular hypertrophy was evaluated on Prevalence of asymmetric septal hypertrophy. Asymmetric septal hypertrophy was present in 5% of hypertensive patients, and its development was not primarily determined by hypertension severity, renin-angiotensin system, or sympathetic activity.

synapsesocial.com/papers/6a0a94f153905a628c7095d8 https://doi.org/https://doi.org/10.1093/eurheartj/4.suppl_g.1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: